SCHEMBL3908602

SCHEMBL3908602

CCOC(=O)C(NS(=O)(=O)c1ccc(Cl)c(F)c1)C(C(F)(F)F)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.41
▸ SLC1A3 P43003 1/20 0.40
▸ SLC1A2 P43004 1/20 0.40
▸ SLC1A1 P43005 1/20 0.40
▸ MMP7 P09237 1/20 0.40
▸ CCR2 P41597 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ BACE1 P56817 1/20 0.37
▸ MMP12 P39900 2/20 0.37
▸ MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3907542 0.86 — —
SCHEMBL3904840 0.85 MAPT (0.37) SLC1A3SLC1A2SLC1A1MAPTBACE1
SCHEMBL3903637 0.81 EEF2K (0.42) SLC1A3SLC1A2SLC1A1MMP7MAPT
SCHEMBL3907469 0.76 PSEN1 (0.55) SLC1A3SLC1A2SLC1A1MMP7CCR2
SCHEMBL3904762 0.74 MMP2 (0.50) SLC1A3SLC1A2SLC1A1MMP7ALDH1A1
SCHEMBL3906115 0.74 MMP2 (0.50) SLC1A3SLC1A2SLC1A1MMP7ALDH1A1
SCHEMBL3904754 0.73 MMP2 (0.51) SLC1A3SLC1A2SLC1A1MMP7LMNA
SCHEMBL2883515 0.70 POLB (0.44) ALDH1A1LMNAMAPT
SCHEMBL2883514 0.70 POLB (0.44) ALDH1A1LMNAMAPT
SCHEMBL6801083 0.70 MMP2 (0.63) SLC1A3SLC1A2SLC1A1MMP7MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS WYETH (US) 2009-09-03 — — US disclosed
US-7550629-B2 4-chloro-N-[(1S)-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]benzenesulfonamide; 4-cyano-N-(3,3,3-trifluoro-1-hydroxymethyl-2-trifluoromethyl-propyl)-benzenesulfonamide; Alzheimer's Disease, amyloid angiopathy, systemic amyloidosis, mild cognitive impairment and Down's syndrome WYETH (US) 2009-06-23 — — US disclosed
US-20070249722-A1 Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors WYETH (US) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221711-A1 TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS APP, PSEN1, BACE1 THRB 2525/4885SLC1A3 3228/4885SLC1A2 3274/4885
US-20070249722-A1 Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors APP, PSEN1, BACE1 THRB 2525/4885SLC1A3 3228/4885SLC1A2 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback